Comprehensive Review of Rheumatoid Arthritis (RA): Pathophysiology, Clinical Outcomes, and Treatment Approaches

Rachana Hallale ¹*, Laxmikant Marewad ², Dr. Padmaja S. Giram ³ , Mr. Mahesh B. Manke⁴ , Dr. Shivakumar S. Ladde ⁵

1 Dept. of Pharmacology, Channabaseshwar College of Pharmacy (Degree), Latur, Maharashtra, IN

2 Dept. of Pharmacology, Channabaseshwar College of Pharmacy (Degree), Latur, Maharashtra, IN       

3 HOD of Dept. of Pharmacology, Channabaseshwar College of Pharmacy (Degree), Latur, Maharashtra, IN

4 Asst. Prof. Dept. of Pharmacology Channabaseshwar College of Pharmacy (Degree) Latur, Maharashtra, IN

5 HOD of Dept. of Pharmacy Practice, Channabaseshwar College of Pharmacy (Degree), Latur, Maharashtra, IN

*Correspondence: rachanahallale366@gmail.com;

INTRODUCTION

The two main characteristics of the systemic autoimmune illness rheumatoid arthritis (RA) are extra-articular involvement and inflammatory arthritis. It is a chronic inflammatory disease that mostly affects the synovial joints and is often caused by a genetic combination with environmental factors, including smoking. If therapy is not administered, the condition usually begins symmetrically in tiny peripheral joints and progresses to the proximal joints [1]. Joint inflammation ultimately leads to bone deterioration, cartilage loss, and joint disintegration. The term "early RA" refers to RA that has symptoms for less than six months.

Since there is no pathognomonic laboratory test for rheumatoid arthritis, it might be difficult to diagnose the illness early. A comprehensive clinical strategy is necessary to detect the disease and prevent irreversible joint damage. Patients with rheumatoid arthritis require both non-pharmacological and pharmaceutical therapies. The current standard of therapy is early treatment with drugs that change the rheumatic condition. Even with therapy, a significant number of individuals eventually develop morbidity and impairment. A comprehensive strategy that includes both pharmaceutical and non-pharmacological treatment (physiotherapy, counseling, and patient education) is needed to enhance clinical results [2].

Signs and symptoms of rheumatoid arthritis may include:

·         Tender, warm, swollen joints

·         Joint stiffness that is usually worse in the mornings and after inactivity

·         Fatigue, fever and loss of appetite

Smaller joints, especially those that connect your toes to your feet and your fingers to your hands, are typically the first to be affected by early rheumatoid arthritis. Symptoms frequently extend to the wrists, knees, ankles, elbows, hips, and shoulders as the illness worsens. The same joints on both sides of your body experience symptoms in the majority of cases [3]
Rheumatoid arthritis patients also experience non-joint signs and symptoms in about 40% of cases. The following areas could be impacted:

·         Skin

·         Eyes

·         Lungs

·         Heart

·         Kidneys

·         Salivary glands

·         Nerve tissue

·         Bone marrow

·         Blood vessels

The symptoms of rheumatoid arthritis might vary in intensity and recurrence. Flares periods of increased disease activity occur in between times of relative remission, when the pain and swelling lessen or disappear. Over time, rheumatoid arthritis can lead to joint deformation and movement [4].

EPIDEMIOLOGY

Rheumatoid arthritis (RA) is a chronic autoimmune disease mostly affecting the joints. Its feature is inflammation of the synovium, which is the lining of the membranes surrounding the joints [5]. Epidemiology of rheumatoid arthritis can provide information on the incidence, prevalence, risk factors, and patterns of distribution of the illness in various demographic groups [6]. Here are a few key facts about the epidemiology of RA.

·         Prevalence and incidence

·         Geographic variation

·         Genetics

·         Environmental factors

·         Age

·         Comorbidities

·         Treatment advance

·         Impact on Quality of life

affects around 1% of adult population globally (0.3%–1.5%). happens two to three times as often in women as in males [7].
Estimated annual occurrence.
Males: 0.1–0.2 per 1000
Women: 0.2–0.4 of 1000 total
For monozygotic twins, there should be a 15%–30% concordance; in comparison to dizygotic twins, there should be a R of 2.5 [8].
The majority of instances are comparable between racial and geographic groups.
increases with age, peaking between 45 and 65 years of age [9].

ETIOLOGY

Rheumatoid arthritis (RA) is believed to be caused by a complex interaction of immunological, environmental, and genetic variables, while the exact etiology of the condition is unclear [10]. Some significant factors that are believed to be involved in the beginning of RA are as follows: [10].
Genetics:  RA has a genetic component because of its propensity to run in families. HLA-DRB1 is a genetic marker associated with an increased risk of getting RA. However, having these genetic markers does not guarantee that a person would develop the illness [11].

·         Autoimmune dysfunction: Because RA is an autoimmune illness, the immune system wrongly targets healthy tissues, particularly the synovial membrane (the lining of the membranes enclosing the joints). What exactly triggered this?

·         Infections: Certain experts have hypothesized that people with a genetic predisposition to RA might react abnormally to bacterial or viral infections. This might eventually lead to the development of the condition.

·         Hormones: Variations in hormone levels, such as those resulting from menopause or pregnancy, might impact the onset and severity of RA. While some pregnant women experience improvement in their symptoms, others may develop RA following childbirth [11].

·         Stress: While persistent stress can not directly cause RA, it can exacerbate the disease's symptoms and trigger flare-ups. The illness could necessitate the application of stress reduction techniques. [12].

PATHOPHYSIOLOGY

The synovitis, swelling, and joint destruction that characterize active RA are the result of a complex autoimmune and inflammatory process that involves components of the innate and adaptive immune systems [13]. tolerance of one's own proteins containing citrulline residues. This protein is produced during translation by the peptidyl arginine deaminase enzyme, which changes arginine residues to citrulline residues. Shared epitope patients produce citrullinated peptides that make the immune system cease considering them to be "self," which triggers an assault on ACPA6. Systemic autoantibody production manifests prior to adhesion molecule synthesis and inflammation, as demonstrated by a comparison of synovial biopsy data from patients positive for ACPA and/or RF with MRI and biopsy data from healthy persons with MRI [14].

PATHOGENESIS

Rheumatoid joint inflammation (RA) has an enigmatic pathophysiology, with a variety of genetic, environmental, immunological, and other factors contributing to the course of events and infection articulation [15]. Although the precise cause of RA is still unknown, genetic and environmental factors may be linked to and trigger a variety of autoimmunity-related responses before any noticeable symptoms appear [16]. Ecological triggers on mucosal surfaces, such as respiratory tract openness to tobacco smoke, are likely to be the first advancements. When peptididyl arginine deiminases (Cushions) are activated, they totally convert arginine to citrulline, changing the peptide's structure.

Therefore, the modified proteins are presented to immune system microbes after being processed by antigen-introducing cells (APCs), such as dendritic cells (DCs). These events can occur in focal lymphoid organs as well as the mucosa, and they can cause the local and fundamental production of antibodies that are coordinated against the changed peptides [17].

Anti-citrullinated protein antibodies (ACPA) and cytokines gradually build up in the circulation in the years before symptoms of RA appear. [18]. The exact sequence of events leading to synovitis is unknown, but it is likely that a second "shock"—such as the creation of an immune complex—is responsible for increasing the vascular permeability of the synovial membrane and activating synovial cells. Consequently, autoantibodies, cytokines, growth factors, chemokines, matrix metalloproteinases (MMPs), small molecule inflammatory mediators, and chemokines all contribute to the development and maintenance of arthritis [19]. While mesenchymal cells in the joint are stimulated by synovial inflammation and can act aggressively, enter the joint, and degrade cartilage, osteoclasts harm subchondral bone. [20]

DIAGNOSIS

Clinical evaluation: A complete medical history and physical examination are usually the first steps in the diagnosis of rheumatoid arthritis (RA) by a rheumatologist or other healthcare provider qualified in the diagnosis and treatment of arthritis and autoimmune diseases.
Symptoms: RA is characterized by a number of symptoms, including joint pain, edema, stiffness, and fatigue. The symptoms can often be symmetrical, meaning they might affect one or both sides of the body, and they commonly impact many joints. Other common symptoms include irregularities of the joints and stiffness in the morning that lasts longer than thirty minutes [21].

Blood testing: Blood tests are often used to confirm the diagnosis of RA. A few of basic blood tests include: [22].
Rheumatoid factor (RF): Many RA patients have increased blood levels of RF, even though not all RA patients exhibit this symptom [23].
Patients with RA often have antibodies in their blood against cyclic citrullinated peptides, or anti-CCPs, which may be a more accurate indicator of the disease. increased rate at which erythrocytes sediment (ESR)
C-reactive protein (CRP): These markers, which may be elevated in RA, demonstrate systemic inflammation [24].
imaging research: MRI, ultrasounds, and X-rays can all be used to detect inflammation and joint damage. These imaging studies can be used to monitor the illness's progression and assess its severity.

Synovial fluid analysis: In certain cases, a medical practitioner will take a fluid sample from a stricken joint to do a synovial fluid study. This can help establish the presence of inflammation and rule out other disorders. [26].
Classification criteria: Rheumatologists commonly use criteria, such as the 2010 American College of Rheumatology/European League Against Rheumatology (ACR/EULAR) criteria, to aid in the diagnosis of RA. These guidelines take into account various clinical and analytical outcomes. [27].

Remember that diagnosing RA may be difficult, therefore it's important to see a medical professional who can evaluate all relevant data and carry out the necessary testing to guarantee an accurate diagnosis. Early diagnosis and appropriate therapy are critical for the optimal management of rheumatoid arthritis, as well as for minimizing joint degeneration and disability [28].

Fig 2 Diagnosis Test For RA

Clinical features

• One of the main symptoms of rheumatoid arthritis is symmetric synovitis [29].
• In addition to this, certain moveable joints are considered extra-articular characteristics [30].
• A recent survey indicates that RA has shown to have a major impact on both a person's functionality and mortality [31].
Research on genetics and epidemiology has identified a number of markers [32].
• There is a correlation between it and the disease's severity and prognosis. and a rise in the use of harsh therapies Accelerated Methotrex Dosing, DMARD Combination Therapy, and Novel DMARD-Containing Regimens [35]
• Use of new biologics, such as leflunomide [36]. response modifiers, such as etanercept, infliximab, adalimumab, anakinra, and rituximab; Qualities that have historically been associated with severe hostility Rheumatoid vasculitis is one of the less prevalent illnesses. [37].

In people with rheumatoid arthritis, clinical impairment advances quickly. growing in significance as a clinical endpoint and stratification factor in medication trials for rheumatoid arthritis. [38].

THERAPY FOR RHEUMATOID ARITHRITIS

Several types of medications are used to treat RA. [40]. Most likely, you will be taking medication to reduce inflammation and discomfort as well as to limit the disease's progression. The exact drugs you require will depend on the severity of your condition, how well you respond to treatment, and your overall health. [41].
drugs that slow the course of rheumatoid arthritis.
Drugs that slow the progression of rheumatoid arthritis help relieve symptoms while preventing joint damage and disability [43].

Options include:

Disease-modifying antirheumatic drugs, or DMARDs DMARDs assist prevent joint degeneration and are usually used as part of the initial line of therapy for rheumatoid arthritis. It may take many months before you completely benefit from DMARDs, and you and your doctor may need to try a few different strategies before deciding on one that suits you both. Common DMARDs include methotrexate, leflunomide (Arava), hydroxychloroquine, and sulfasalazine (azulfidine) [44].

biological warfare If injection-based biological treatment is not effective on its own, it is usually used in combination with DMARDs. Biologic treatment is a unique drug that prevents the immune system from attacking the joints. Common biologic medications are etanercept (Enbrel) and infliximab (Remicade) [45].
inhibitor of Janus kinase (JAK) inhibitor of Janus kinase (JAK) Those who are intolerant to or have not reacted well to conventional DMARDs may benefit from a new family of drugs known as JAK inhibitors [46]. Common JAK inhibitors include baricitinib (Olumiant) and tofacitinib (Xeljanz) [47].
Drugs that lessen rheumatoid arthritis pain and inflammation:
A lot of RA sufferers also use medication to help manage their pain.

You may take these drugs on a daily basis, as needed, or during a flare-up, depending on your condition and the treatment plan you and your doctor decide upon. Pain-relieving options include: [51]

·         NSAID Pain and inflammation are reduced by nonsteroidal anti-inflammatory medications (NSAIDs). Your physician may prescribe stronger NSAIDs or suggest over-the-counter options such ibuprofen or naproxen sodium [52].

·         Inhibitors of COX-2 In addition, COX-2 inhibitors like Celebrex lessen pain and inflammation. Compared to NSAIDs, they are supposed to be safer to take on a daily basis and have less negative effects [53].

·         Steroids have the ability to lessen pain and inflammation. Steroids can be taken as tablets or as an injection. Steroids should only be used temporarily due to their potential for severe negative effects [57].

Dietary adjustments and nutritional supplements
Some claim that altering their diets helps lessen the symptoms of their RA. This usually entails avoiding meals heavy in sugar, artificial chemicals, and carbs as well as adhering to an anti-inflammatory diet [58].
An anti-inflammatory diet includes foods such as: [59]

• fish
• berries
• avocados
• peppers
• dark leafy green vegetables
• tomatoes
• extra-virgin olive oil
• dark chocolate

TREATMENT

For RA patients, the primary goals are early diagnosis and start of medication to avoid irreversible joint degradation [60]. The 2014 International Task Force Guidelines [61] provide the following recommendations for the treatment of RA.
• The major goals of treatment are to achieve long-term clinical remission and to maximize quality of life when there are no symptoms or indicators that indicate the presence of an inflammatory illness [62].
• If clinical remission is not achievable, low disease activity might serve as a good stand-in [63]. A monthly evaluation of the disease activity is recommended for patients with moderate to severe disease activity [64].
• Individuals with modest disease activity or those in clinical trials should have their disease activity assessed every three to six months.

Many clinical evaluation techniques have been developed to assist physicians in assessing the disease activity of individuals with RA [66]. The American College of Rheumatology (ACR) revised its recommendation in 2019 and recommended using the following assessment tools since they met the evaluation's basic standards [67]. Laboratory tests, provider and patient feedback, and patient input are all included in the user-friendly DAS28, CDAI, and RAPID3 combo in clinical practice [68].

·         Clinical Disease Activity Index (CDAI) 

·         Disease Activity Score (DAS)

·         Disease Activity Score 28 Joints (DAS28-ESR/CRP)

·         Patient-Derived DAS28

·         Hospital Universitario La Princesa Index (HUPI)

·         Multi-Biomarker Disease Activity Score (MBDA score, VECTRA DA)

·         Rheumatoid Arthritis Disease Activity Index (RADAI)

·         Rheumatoid Arthritis Disease Activity Index 5 (RADAI-5)

·         Routine Assessment of Patient Index Data 3 (RAPID3)

·         Routine Assessment of Patient Index Data 5 (RAPID5) [69,70]

STAGING

Stages of RA as Defined by the ACR

• Stage 1: X-rays show no harmful alterations.
• Stage 2: No joint deformity but periarticular osteoporosis and subchondral bone degeneration as seen on X-rays.
• Stage 3: X-ray evidence of bone and cartilage loss, together with joint malformation and periarticular osteoporosis.
• Stage 4: Characteristics of Stage 3 with the presence of fibrous or bony ankylosis [71,72].

Herbal plants for Rheumatoid arthritis

Table 1. Herbal Plant for RA

REFERENCES       

1.       Lee JE, Kim IJ, Cho MS, Lee J. A Case of Rheumatoid Vasculitis Involving Hepatic Artery in Early Rheumatoid Arthritis. J Korean Med Sci. 2017 Jul;32(7):1207-1210.

2.       Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol. 2007 Jul 12

3.       McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 

4.       Balsa A, Cabezón A, Orozco G, Cobo T, Miranda-Carus E, López-Nevot MA, Vicario JL, Martín-Mola E, Martín J, Pascual-Salcedo D. Influence of HLA DRB1 alleles in the susceptibility of rheumatoid arthritis and the regulation of antibodies against citrullinated proteins and rheumatoid factor. Arthritis Res Ther. 2010;12(2):R62.

5.       van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis. 2011.

6.       Nielen MM, van Schaardenburg D, Reesink H, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004

7.       Lund-Olesen K. Oxygen tension in synovial fluids. Arthritis Rheum. 1970

8.       Allender E. The prevalence of rheumatoid arthri- tis: present knowledge and some future directions of research. In: Lawrence RC, Shulman LE, eds. Epidemiology of the rheumatic diseases. New York: Gower Medical Publishing Ltd., 1984.

9.       Spector TD. Epidemiology of rheumatoid arthri- tis. Rheum Dis Clin North Am 1990

10.     Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid ar- thritis. Arthritis Rheum 1988

11.   . Dugowson C, Nelson JL, Koepsell TD. Evaluation of the 1987 revised criteria for rheumatoid arthri- tis in a cohort of newly diagnosed female patients. Arthritis Rheum 1990.

12.    Levin RW, Bomalaski JS, Reginato A, et al. Clin- ical assessment of the 1987 revised American Rheumatism Association criteria for rheumatoid arthritis. (Abstract). Arthritis Rheum 1989.

13.     Silman AJ. The 1987 American Rheumatism As- sociation criteria for RA. Br J Rheumatol 1988 

14.    Linos A, Worthington JW, O'Fallon WM, et al. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of its incidence, prevalence, and mortality. Am J Epidemiol 1980.

15.     Hochberg MC. Changes in the incidence and prev- alence of rheumatoid arthritis in England and Wales, 1970-1982. Semin Arthritis Rheum 1990.

16.   Silman AJ, Oilier W, Hayton RM, et al. Twin concordance rates for rheumatoid arthritis: pre- liminary results from a nationwide study.

17.   Roudier J, Petersin J, Rhodes GH, et al. Suscep- tibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR B-l chain and the Epstein-Barr virus glycoprotein gpllO. Proc Natl Acad Sci USA 1989

18.   . Silman AJ, Vandenbroucke JP, eds. Female sex hormones and rheumatoid arthritis. Br J Rheu- matol 1989

19.    Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1977.

20.    Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid ar- thritis: an overview of the analytic epidemiologic studies using meta-analysis. J Clin Epidemiol 1990.

21.    Vandenbroucke JP, Valkenburg HA, Boersma JW, et al. Oral contraceptives and rheumatoid arthritis: further evidence for a protective effect. Lancet 1982

22.    Allebeck P, Aholm A, Ljungstrom K, et al. Do oral contraceptives reduce the incidence of rheumatoid arthritis? Scand J Rheumatol 1984

23.    Del Junco DJ, Annegers JF, Luthra HS, et al. Do oral contraceptives prevent rheumatoid arthritis? JAMA 1985

24.   Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006 Jul.

25.   Ramos-Remus C, Castillo-Ortiz JD, Aguilar-Lozano L, Padilla-Ibarra J, Sandoval-Castro C, Vargas-Serafin CO, de la Mora-Molina H, Ramos-Gomez A, Sanchez-Ortiz A, Avila-Armengol H, Aceves-Avila FJ. Autoantibodies in prediction of the development of rheumatoid arthritis among healthy relatives of patients with the disease. Arthritis Rheumatol. 2015

26.   Bemis EA, Demoruelle MK, Seifert JA, Polinski KJ, Weisman MH, Buckner JH, Gregersen PK, Mikuls TR, ODell JR, Keating RM, Deane KD, Holers VM, Norris JM. Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting. Ann Rheum Dis. 2021 Feb

27.   Kortekangas P, Aro HT, Tuominen J, Toivanen A. Synovial fluid leukocytosis in bacterial arthritis vs. reactive arthritis and rheumatoid arthritis in the adult knee. Scand J Rheumatol. 1992

28.   Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol. 1989 May

29.   McQueen FM. The use of MRI in early RA. Rheumatology (Oxford). 2008 Nov

30.   McQueen FM, Stewart N, Crabbe J, Robinson E, Yeoman S, Tan PL, McLean L. Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis. 1999 Mar

31.   Cornec D, Varache S, Morvan J, Devauchelle-Pensec V, Berthelot JM, Le Henaff-Bourhis C, Hoang S, Martin A, Chalès G, Jousse-Joulin S, Saraux A. Comparison of ACR 1987 and ACR/EULAR 2010 criteria for predicting a 10-year diagnosis of rheumatoid arthritis. Joint Bone Spine. 2012 Dec

32.   Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep

33.   de Hair MJ, van de Sande MG, Ramwadhdoebe TH, Hansson M, Landewé R, van der Leij C, Maas M, Serre G, van Schaardenburg D, Klareskog L, Gerlag DM, van Baarsen LG, Tak PP. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 2014 Mar

34.   McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec

35.   de Brito Rocha S, Baldo DC, Andrade LEC. Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. 2019 Jan 17;59(1):2. 

36.   Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021 Jan

37.   Lin YJ, Anzaghe M, Schülke S. Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells. 2020 Apr 03;9(4) 

38.   .Kondo N, Kuroda T, Kobayashi D. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis. Int J Mol Sci. 2021 Oct 10

39.   Lally F, Smith E, Filer A, Stone MA, Shaw JS, Nash GB, Buckley CD, Rainger GE. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum. 2005 Nov

40.   Demasi M, Cleland LG, Cook-Johnson RJ, James MJ. Effects of hypoxia on the expression and activity of cyclooxygenase 2 in fibroblast-like synoviocytes: interactions with monocyte-derived soluble mediators. Arthritis Rheum. 2004 Aug

41.   Chua-Aguilera CJ, Möller B, Yawalkar N. Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clin Rev Allergy Immunol. 2017 Dec

42.   Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 Sep

43.   Koskinen E, Hannonen P, Sokka T. Palindromic rheumatism: longterm outcomes of 60 patients diagnosed in 1967-84. J Rheumatol. 2009 Sep

44.   Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G, Russell AS, Suarez-Almazor ME. Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol. 2000 Jan

45.   Lehtinen JT, Kaarela K, Belt EA, Kautiainen HJ, Kauppi MJ, Lehto MU. Incidence of acromioclavicular joint involvement in rheumatoid arthritis: a 15 year endpoint study. J Rheumatol. 1999 Jun

46.   Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol. 2005 Aug

47.   Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Vassallo R, Gabriel SE, Matteson EL. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2010 Jun

48.   Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, Kim SC. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatology (Oxford). 2021 Aug

49.   Samhouri BF, Vassallo R, Achenbach SJ, Kronzer VL, Davis JM, Myasoedova E, Crowson CS. Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort. Arthritis Care Res (Hoboken). 2022 Dec

50.   Correia CS, Briones MR, Guo R, Ostrowski RA. Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease. Clin Rheumatol. 2019 Apr

51.   Castellanos-Moreira R, Rodriguez-Garcia SC, Cabrera-Villalba S, Gomara MJ, Salvador G, Ruiz-Esquide V, Ramirez J, Inciarte-Mundo J, Morla R, Garcia-Moreno C, Cuervo A, Gómez-Puerta JA, Cañete JD, Haro I, Sanmarti R. Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. Ther Adv Musculoskelet. 

52.   England BR, Duryee MJ, Roul P, Mahajan TD, Singh N, Poole JA, Ascherman DP, Caplan L, Demoruelle MK, Deane KD, Klassen LW, Thiele GM, Mikuls TR. Malondialdehyde-Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2019 Sep

53.   Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2016 Jan

54.   Solomon DH, Husni ME, Wolski KE, Wisniewski LM, Borer JS, Graham DY, Libby P, Lincoff AM, Lüscher TF, Menon V, Yeomans ND, Wang Q, Bao W, Berger MF, Nissen SE., PRECISION Trial Investigators. Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 Apr

55.   Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lϋscher TF, Menon V, Brennan DM, Wisniewski LM, Nissen SE, Borer JS. The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. Am J Med. 2017 Dec

56.   Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A, Berenbaum F, Breedveld F, Dieleman P, Dougados M, MacDonald T, Mola EM, Mets T, Van den Noortgate N, Stoevelaar H. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011 May

57.   Ashworth NL, Peloso PM, Muhajarine N, Stang M. A population based historical cohort study of the mortality associated with nabumetone, Arthrotec, diclofenac, and naproxen. J Rheumatol. 2004 May

58.   van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med. 2002 Jan 01

59.   Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW., Utrecht Rheumatoid Arthritis Cohort Study Group. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012 Mar 06

60.   Krause D, Mai A, Klaassen-Mielke R, Timmesfeld N, Trampisch U, Rudolf H, Baraliakos X, Schmitz E, Fendler C, Klink C, Boeddeker S, Saracbasi-Zender E, Christoph HJ, Igelmann M, Menne HJ, Schmid A, Rau R, Wassenberg S, Sonuc N, Ose C, Schade-Brittinger C, Trampisch HJ, Braun J. The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis Rheumatol. 2022 Oct

61.   Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009 Jul

62.   Braun J, Kästner P, Flaxenberg P, Währisch J, Hanke P, Demary W, von Hinüber U, Rockwitz K, Heitz W, Pichlmeier U, Guimbal-Schmolck C, Brandt A; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008 Jan

63.   Hoekstra M, Haagsma C, Neef C, Proost J, Knuif A, van de Laar M. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol. 2006 Mar. 

64.   O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, Fernandez A, Blakely K, Wees S, Stoner J, Hadley S, Felt J, Palmer W, Waytz P, Churchill M, Klassen L, Moore G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 May. 

65.   O'Dell JR, Mikuls TR, Taylor TH, Ahluwalia V, Brophy M, Warren SR, Lew RA, Cannella AC, Kunkel G, Phibbs CS, Anis AH, Leatherman S, Keystone E., CSP 551 RACAT Investigators. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013 Jul

66.   Sauer BC, Teng CC, Tang D, Leng J, Curtis JR, Mikuls TR, Harrison DJ, Cannon GW. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2017 Mar

67.   Erhardt DP, Cannon GW, Teng CC, Mikuls TR, Curtis JR, Sauer BC. Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. Arthritis Care Res (Hoboken). 2019 Oct. 

68.   Curtis JR, Palmer JL, Reed GW, Greenberg J, Pappas DA, Harrold LR, Kremer JM. Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021 Aug. 

69.   Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann Rheum Dis. 2013 Dec. 

70.   Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013 Dec. 

71.   Porter D, van Melckebeke J, Dale J, Messow CM, McConnachie A, Walker A, Munro R, McLaren J, McRorie E, Packham J, Buckley CD, Harvie J, Taylor P, Choy E, Pitzalis C, McInnes IB. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Lancet. 2016 Jul 16. 

72.   Genovese MC, Pacheco-Tena C, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente RM, Nash P, Simon-Campos JA, Box J, Legerton CW, Nasonov E, Durez P, Elegbe A, Wong R, Li X, Banerjee S, Alten R. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial. J Rheumatol. 2018 Aug. 

73.   Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013 Apr

74.   Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Arthritis Rheumatol. 2017 Feb. 

75.   Wallenstein GV, Kanik KS, Wilkinson B, Cohen S, Cutolo M, Fleischmann RM, Genovese MC, Gomez Reino J, Gruben D, Kremer J, Krishnaswami S, Lee EB, Pascual-Ramos V, Strand V, Zwillich SH. Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016 May-Jun. 

76.   Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM. Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register. Arthritis Rheumatol. 2017 Aug. 

77.   Paul BJ, Kandy HI, Krishnan V. Pre-rheumatoid arthritis and its prevention. Eur J Rheumatol. 2017 Jun. 

78.   Holmqvist M, Mantel Ä, Wållberg-Jonsson S, James S, Jernberg T, Askling J. Findings on Coronary Angiographies in Patients With Rheumatoid Arthritis and Ischemic Heart Disease: Are They Different From Patients Without Rheumatoid Arthritis? Arthritis Care Res (Hoboken). 2021 May. 

79.   Solomon DH, Goodson NJ, Katz JN, Weinblatt ME, Avorn J, Setoguchi S, Canning C, Schneeweiss S. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006 Dec. 

80.   Martin-Trujillo A, van Rietschoten JG, Timmer TC, Rodríguez FM, Huizinga TW, Tak PP, Marsal S, Ibrahim SM, Dijkmans BA, van der Pouw Kraan TC, Verweij CL. Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis. Ann Rheum Dis. 2010 Jun

81.   Atzeni F, Masala IF, di Franco M, Sarzi-Puttini P. Infections in rheumatoid arthritis. Curr Opin Rheumatol. 2017 Jul

82.   Carbone F, Bonaventura A, Liberale L, Paolino S, Torre F, Dallegri F, Montecucco F, Cutolo M. Atherosclerosis in Rheumatoid Arthritis: Promoters and Opponents. Clin Rev Allergy Immunol. 2020 Feb

83.   Nicolau J, Lequerré T, Bacquet H, Vittecoq O. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017 Jul

84.   Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T., QUEST-RA Group. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther. 2008]

85.   Ozen G, Pedro S, Michaud K. The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. J Rheumatol. 2021 May

86.   Xie F, Chen L, Yun H, Levitan EB, Curtis JR. Benefits of Methotrexate Use on Cardiovascular Disease Risk Among Rheumatoid Arthritis Patients Initiating Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol. 2021 Jun

87.   Klein A, Polliack A, Gafter-Gvili A. Rheumatoid arthritis and lymphoma: Incidence, pathogenesis, biology, and outcome. Hematol Oncol. 2018 Dec

88.   Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006 Mar

89.   Hellgren K, Baecklund E, Backlin C, Sundstrom C, Smedby KE, Askling J. Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Arthritis Rheumatol. 2017 Apr

90.   Jin S, Hsieh E, Peng L, Yu C, Wang Y, Wu C, Wang Q, Li M, Zeng X. Incidence of fractures among patients with rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2018 Jun

91.   Kim SC, Schneeweiss S, Liu J, Solomon DH. Risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct

92.   Bacani AK, Gabriel SE, Crowson CS, Heit JA, Matteson EL. Noncardiac vascular disease in rheumatoid arthritis: increase in venous thromboembolic events? Arthritis Rheum. 2012 Jan